Last reviewed · How we verify
Amlodipin, losartan, HCTZ
At a glance
| Generic name | Amlodipin, losartan, HCTZ |
|---|---|
| Also known as | LOSANET AM PLUS |
| Sponsor | Pharmaceutical Research Unit, Jordan |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Fixed-Free HTN Trial (PHASE4)
- Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipin, losartan, HCTZ CI brief — competitive landscape report
- Amlodipin, losartan, HCTZ updates RSS · CI watch RSS
- Pharmaceutical Research Unit, Jordan portfolio CI